In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on Arcus Biosciences, with a price target of $33.00. The company’s shares closed last Friday at $14.60.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Driscoll is an analyst with an average return of -0.9% and a 37.95% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Crescent Biopharma, Adicet Bio, and Arcus Biosciences.
Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $32.50, which is a 122.60% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.
The company has a one-year high of $18.98 and a one-year low of $6.50. Currently, Arcus Biosciences has an average volume of 840.3K.
Read More on RCUS:
Disclaimer & DisclosureReport an Issue
- Arcus Biosciences price target raised to $54 from $47 at Citi
- Positive Outlook for Arcus Biosciences Driven by Promising Phase 2 Trial Results and Broader Patient Applicability
- Arcus announces first OS results from Arm A1 of Phase 2 EDGE-Gastric study
- Arcus Biosciences price target raised to $39 from $32 at Truist
- Arcus Biosciences’ Casdatifan Shows Superior Efficacy and Safety in ccRCC Treatment, Supporting Buy Rating
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
